Literature DB >> 6915901

Perioperative prophylactic use of antibiotics in surgery: principles and practice.

M Shapiro.   

Abstract

Prophylactic use of antimicrobics represents about 30% of total hospital use of these agents. Previous studies in animal models have suggested that timing of such prophylaxis is crucial, to the extent of the existence of a "critical period" for effective administration. This phenomenon has further been shown to exist in man, in numerous double-blind, controlled clinical trials in various types of surgical wounds. On these bases, we introduced new prophylactic protocols in a university hospital, specifically directed at reducing infection in high-risk procedures. Surveillance was conducted by infection control nurses, and one antibiotic-day was the comparative unit. Infection rates were markedly diminished under these new protocols. Total usage of antimicrobial drugs also decreased by 38% over previous rates. The rationale for limiting prophylaxis to a circumscribed period was clearly demonstrated, although the exact mechanisms responsible for this effect are, as yet, unclear.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6915901     DOI: 10.1017/s019594170005709x

Source DB:  PubMed          Journal:  Infect Control        ISSN: 0195-9417


  3 in total

1.  Pharmacokinetics and tissue distribution of intravenous ofloxacin for antibiotic prophylaxis in biliary surgery.

Authors:  A R Gascón; E Campo; R M Hernández; B Calvo; J Errasti; J L Pedraz
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

2.  Postoperative infections in immunocompromised patients after oncological surgery.

Authors:  J Y Ranchere; B Gordiani; P Bachmann
Journal:  Support Care Cancer       Date:  1995-11       Impact factor: 3.603

3.  Cefminox versus Cefoxitin in Hysterectomy Prophylaxis : Clinical Efficacy and Serum and Tissue Concentrations.

Authors:  R Garrido; A Novo; S Quintana; M A Macía; L Carrasco; M J de Dios; J M Romo; M Sánchez; M Vargas; M Maciá; F Lapuente; Y Mieza; P Coronet; M Gimeno; A J Carcas; J Frías; V Caballero Fernández
Journal:  Clin Drug Investig       Date:  1997-06       Impact factor: 2.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.